Sign In
Buy LLY
$1,131.42
+6.04 (+0.537%)
At Close: Jun 05, 2026
Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition
06:00am, Thursday, 06'th Jun 2024
Growth stocks continue to drive the market and investor portfolios higher. Several companies with strong catalysts are seeing their sales and profits rise, and that is pushing their share prices to ne
Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half
06:00am, Thursday, 06'th Jun 2024
There's certainly some level of comfort in bidding up the same names as everybody else. But the most satisfying returns stem from momentum stocks that you identified before the big wave.
Eli Lilly Japan's Business Outlook
11:01pm, Wednesday, 05'th Jun 2024
Simone Thomsen, Representative Director and President of Eli Lilly Japan, discusses her outlook for the pharmaceutical giant's Japan business and strategy in providing diabetes, Alzheimer's and other
Alphabet taps Eli Lilly executive as new CFO
02:37pm, Wednesday, 05'th Jun 2024
Alphabet (GOOGL, GOOG) announced Anat Ashkenazi, the current executive vice president and CFO of Eli Lilly (LLY), will become the tech giant's new CFO effective July 31. Mizuho senior analyst Jared Ho
Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?
02:05pm, Wednesday, 05'th Jun 2024
Eli Lilly has been outperforming the S&P 500. The company's blockbuster drug Mounjaro has been approved in China, resulting in high demand and a strong earnings report. The five-year target price for
Alphabet Names Eli Lilly Executive Ashkenazi as CFO
09:59am, Wednesday, 05'th Jun 2024
Alphabet Inc. tapped Eli Lilly & Co. executive Anat Ashkenazi as its new chief financial officer effective July 31, replacing Ruth Porat who announced last year she planned to step down. Ed Ludlow rep
Who is Anat Ashkenazi, the Eli Lilly veteran becoming Google's next CFO?
08:28am, Wednesday, 05'th Jun 2024
As Alphabet Inc. looks to fill a vacancy in its senior ranks, it's turning to a longtime Eli Lilly and Co. veteran who helped build the healthcare company into a juggernaut.
Alphabet's new CFO is Eli Lilly's Anat Ashkenazi
08:17am, Wednesday, 05'th Jun 2024
Alphabet has announced who its new chief financial officer (CFO) will be, revealing today that it has hired pharmaceutical giant Eli Lilly and Company's CFO Anat Ashkenazi.
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFO
08:09am, Wednesday, 05'th Jun 2024
Alphabet taps Eli Lilly's Anat Ashkenazi as new CFO
Eli Lilly finance chief to join Alphabet
07:56am, Wednesday, 05'th Jun 2024
Eli Lilly said on Wednesday its chief financial officer Anat Ashkenazi has resigned after more than two decades at the U.S. drugmaker.
Lilly announces departure of Anat Ashkenazi, chief financial officer
07:45am, Wednesday, 05'th Jun 2024
INDIANAPOLIS , June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the
S&P Stocks To Trade In June
06:00am, Wednesday, 05'th Jun 2024
For this month, the cycle/relative strength concept is applied. First, the S&P 500 stocks are ranked from the best performer to the worst by calculating the expected return in that month.
Mounjaro becomes second weight loss drug to receive NICE green light
03:35am, Wednesday, 05'th Jun 2024
The National Institute for Health and Care Excellence (NICE) in England has approved a second drug to combat obesity, offering a more effective alternative to semaglutide. The newly approved drug, tir
Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript)
01:33pm, Tuesday, 04'th Jun 2024
Eli Lilly and Company (NYSE:LLY ) Lilly Oncology ASCO Investor Event June 2, 2024 8:30 PM ET Company Participants Jake Van Naarden - Executive VP & President of Loxo Lillian Smyth - Senior Vice Presid
Britain considers offering Lilly weight-loss drug on better terms than Wegovy
12:59pm, Tuesday, 04'th Jun 2024
Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for
